PetMed Express, Inc. Announces Appointment of Peter Batushansky to Board of Directors
PetMed Express (NASDAQ: PETS) has appointed Peter Batushansky to its Board of Directors, effective April 09, 2025. Batushansky, currently a Partner at L2 Capital Partners, brings over 20 years of experience in retail, pet, healthcare, and private equity sectors, including executive roles at WebEyeCare and Allivet.
The appointment marks the third independent director addition since 2024, bringing the board to seven members, with six being independent. Dr. Gian Fulgoni, longtime board member and former Chairman, will retire at the 2025 annual shareholders' meeting.
This appointment follows recent leadership changes, including Leslie C. G. Campbell as Board Chairman in Q4 2024, Sandra Campos as CEO and President in Q1 2025, and new executives in CFO, CAO, COO, and Chief Digital roles. Justin Mennen and Leah Solivan joined the Board in Q2 2025.
PetMed Express (NASDAQ: PETS) ha nominato Peter Batushansky nel suo Consiglio di Amministrazione, con effetto dal 9 aprile 2025. Batushansky, attualmente Partner presso L2 Capital Partners, porta con sé oltre 20 anni di esperienza nei settori del retail, degli animali domestici, della salute e del private equity, inclusi ruoli dirigenziali in WebEyeCare e Allivet.
Questa nomina segna l'aggiunta del terzo direttore indipendente dal 2024, portando il consiglio a sette membri, sei dei quali sono indipendenti. Il Dr. Gian Fulgoni, membro di lunga data del consiglio e ex Presidente, si ritirerà durante l'assemblea annuale degli azionisti del 2025.
Questa nomina segue recenti cambiamenti nella leadership, tra cui Leslie C. G. Campbell come Presidente del Consiglio nel Q4 2024, Sandra Campos come CEO e Presidente nel Q1 2025, e nuovi dirigenti nei ruoli di CFO, CAO, COO e Chief Digital. Justin Mennen e Leah Solivan si sono uniti al Consiglio nel Q2 2025.
PetMed Express (NASDAQ: PETS) ha nombrado a Peter Batushansky en su Junta Directiva, con efecto a partir del 9 de abril de 2025. Batushansky, actualmente socio en L2 Capital Partners, aporta más de 20 años de experiencia en los sectores de retail, mascotas, salud y capital privado, incluidos roles ejecutivos en WebEyeCare y Allivet.
Esta designación marca la tercera adición de un director independiente desde 2024, llevando la junta a siete miembros, de los cuales seis son independientes. El Dr. Gian Fulgoni, miembro de larga data de la junta y ex presidente, se retirará en la reunión anual de accionistas de 2025.
Esta designación sigue a recientes cambios en el liderazgo, incluyendo a Leslie C. G. Campbell como Presidente de la Junta en el Q4 de 2024, a Sandra Campos como CEO y Presidente en el Q1 de 2025, y nuevos ejecutivos en los roles de CFO, CAO, COO y Chief Digital. Justin Mennen y Leah Solivan se unieron a la Junta en el Q2 de 2025.
PetMed Express (NASDAQ: PETS)는 2025년 4월 9일부터 Peter Batushansky를 이사로 임명했습니다. 현재 L2 Capital Partners의 파트너인 Batushansky는 소매, 애완동물, 헬스케어 및 사모펀드 분야에서 20년 이상의 경험을 보유하고 있으며, WebEyeCare와 Allivet에서의 경영직을 포함합니다.
이번 임명은 2024년 이후 세 번째 독립 이사 추가로, 이사회는 총 7명으로 구성되며 그 중 6명이 독립 이사입니다. 오랜 이사회 멤버이자 전 회장인 Gian Fulgoni 박사는 2025년 연례 주주 총회에서 은퇴할 예정입니다.
이번 임명은 최근 리더십 변화에 따른 것으로, 2024년 4분기에 Leslie C. G. Campbell이 이사회 의장으로, 2025년 1분기에 Sandra Campos가 CEO 및 사장으로 임명되었으며, CFO, CAO, COO 및 Chief Digital 역할에 새로운 경영진이 합류했습니다. Justin Mennen과 Leah Solivan은 2025년 2분기에 이사회에 합류했습니다.
PetMed Express (NASDAQ: PETS) a nommé Peter Batushansky à son Conseil d'Administration, à compter du 9 avril 2025. Batushansky, actuellement partenaire chez L2 Capital Partners, apporte plus de 20 ans d'expérience dans les secteurs de la vente au détail, des animaux de compagnie, de la santé et du capital-investissement, y compris des postes de direction chez WebEyeCare et Allivet.
Cette nomination marque le troisième ajout d'un directeur indépendant depuis 2024, portant le conseil à sept membres, dont six sont indépendants. Le Dr Gian Fulgoni, membre de longue date du conseil et ancien président, prendra sa retraite lors de l'assemblée annuelle des actionnaires de 2025.
Cette nomination fait suite à des changements récents dans la direction, notamment Leslie C. G. Campbell en tant que président du conseil au T4 2024, Sandra Campos en tant que PDG et présidente au T1 2025, ainsi que de nouveaux dirigeants dans les rôles de CFO, CAO, COO et Chief Digital. Justin Mennen et Leah Solivan ont rejoint le conseil au T2 2025.
PetMed Express (NASDAQ: PETS) hat Peter Batushansky in seinen Verwaltungsrat berufen, mit Wirkung zum 9. April 2025. Batushansky, der derzeit Partner bei L2 Capital Partners ist, bringt über 20 Jahre Erfahrung in den Bereichen Einzelhandel, Haustiere, Gesundheitswesen und Private Equity mit, einschließlich leitender Positionen bei WebEyeCare und Allivet.
Die Ernennung ist die dritte unabhängige Direktorenzugabe seit 2024, wodurch der Vorstand auf sieben Mitglieder erhöht wird, von denen sechs unabhängig sind. Dr. Gian Fulgoni, langjähriges Vorstandsmitglied und ehemaliger Vorsitzender, wird sich bei der Hauptversammlung der Aktionäre 2025 zurückziehen.
Diese Ernennung folgt auf kürzliche Führungswechsel, darunter Leslie C. G. Campbell als Vorsitzende des Vorstands im Q4 2024, Sandra Campos als CEO und Präsidentin im Q1 2025 sowie neue Führungskräfte in den Rollen CFO, CAO, COO und Chief Digital. Justin Mennen und Leah Solivan traten im Q2 2025 dem Vorstand bei.
- Board strengthened with three new independent directors since 2024
- New director brings 20+ years of relevant industry experience
- Comprehensive leadership transformation with new CEO, CFO, CAO, COO, and Chief Digital Officer
- Enhanced board independence with 6 out of 7 directors being independent
- Loss of experienced board member Dr. Gian Fulgoni through retirement
- Significant leadership turnover may cause temporary operational disruption
Former pet industry executive with more than 20 years of experience across retail, pet, healthcare, and private equity
Third independent director to join the Board since 2024
Longtime board member and former Chairman Dr. Gian Fulgoni will retire
DELRAY BEACH, Fla., April 09, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc., parent company of PetMeds and PetCareRx, (Nasdaq: PETS) (the "Company") today announced the appointment of Peter Batushansky to the Company’s Board of Directors (“the Board”), effective April 09, 2025. Mr. Batushansky is currently a Partner at L2 Capital Partners and brings to the Board more than 20 years of experience across retail, pet, healthcare and private equity, including executive leadership roles at WebEyeCare and Allivet. Dr. Gian Fulgoni, longtime board member and former Chairman, has communicated his intention to retire from the Board when his term expires at the 2025 annual shareholders’ meeting.
“We are thrilled to welcome Peter to the Board of Directors,” said Leslie C. G. Campbell, Chairman of the Board. “His strategic vision and extensive leadership experience will bring invaluable perspective as we execute our transformation plan and drive shareholder value creation. Peter’s proven ability scaling businesses in retail, pet and healthcare aligns with our ambitions, and his skills complement and expand on those of the rest of the Board. We also want to take this opportunity to recognize and thank our colleague Gian Fulgoni for his dedicated service as a Board member and former Chairman, and we look forward to working with him closely through the remainder of his current term.”
Mr. Batushansky’s appointment adds incremental talent to the Board, underscoring the continued commitment to recruit new independent and highly qualified directors whose experiences and skillsets support the Company’s transformation strategy to deliver long-term shareholder returns. The appointment of Ms. Campbell as Chairman of the Board in Q4 2024 and Ms. Campos’ appointment as the Company’s new CEO and President in Q1 2025 signaled the start of this leadership transformation, followed by key hires in the roles of Chief Financial Officer, Chief Accounting Officer, Chief Operating Officer, and Chief Digital and Technology Officer. Justin Mennen and Leah Solivan joined the Board during Q2 2025. With the appointment of Mr. Batushansky, the Board will be comprised of seven highly qualified and experienced directors, six of whom are independent, and three of whom have been added since 2024.
Sandra Campos, President and CEO commented, “Peter brings not only deep industry expertise and an exceptional track record in e-commerce, but also the mindset of a founder—practical, visionary, and deeply committed. His alignment with our mission and values is clear, and we’re genuinely excited to welcome him to the Board. We look forward to the perspective and energy he’ll bring as we continue to move our value creation strategy forward.”
“It’s exciting to join the Board at such a pivotal time in the Company’s history,” said Mr. Batushansky. “PetMeds is well-positioned to capitalize on its strong heritage as a pioneer in online pet pharmacy to significantly expand its business across the broader pet wellness ecosystem. I look forward to working closely with my fellow directors and this talented, passionate management team to shape and execute a successful strategy to drive growth, profitability, and shareholder value.”
Ms. Campbell added, “The appointment of Peter Batushansky to our Board, as well as the recent appointments of Justin Mennen and Leah Solivan, are the result of our strong ongoing focus on strategic board composition and refreshment, aligning the Board’s skillsets with the oversight needed to drive shareholder value.”
About Peter Batushansky
Mr. Batushansky has more than 20 years of experience across multiple industries including retail, pet, healthcare, and private equity. He has extensive experience in senior leadership roles, including as the former Chief Executive Officer of Allivet, a retailer of pet healthcare products from 2017-2021, and was the Chief Executive Officer of WebEyeCare, a retailer of optical products from 2010-2016.
Currently, Mr. Batushansky is a Partner at L2 Capital Partners, a Pennsylvania-based private equity firm where he serves as a board member and advisor across portfolio companies. Mr. Batushansky prior private equity experience includes roles at Milestone Partners and Roark Capital. He holds a B.A. from Temple University in Philadelphia, Pennsylvania.
About PetMed Express, Inc.
Founded in 1996, PetMeds is a leader in the consumer pet healthcare sector. As a national online retailer with expert pharmacists and licenses across fifty states, PetMeds.com and PetCareRx.com deliver top branded pharmaceuticals, generics, compounded prescription medications and OTC supplements and vitamins that help pets live longer, healthier lives. The Company strives to offer unparalleled value and convenience that enhance wellness and longevity for dogs, cats, and horses. PetMeds and PetCareRx provide essential pet health offerings through their websites, www.PetMeds.com and www.PetCareRx.com.
Forward Looking Statement
This press release may contain “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties, including the Company’s ability to meet the objectives included in its business plan. Important factors that could cause results to differ materially from those indicated by such forward-looking statements are set forth in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections in the Company’s Annual Report on Form 10-K for the year ended March 31, 2024, filed on June 14, 2024. The Company’s future results may also be impacted by other risk factors listed from time to time in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, the Company's Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and periodic filings on Form 8-K. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements, other than as may be required by law. If the Company does update one or more forward-looking statements, no inference should be made that the Company will make additional updates with respect to those or other forward-looking statements.
Investor Contact:
ICR, LLC
John Mills
(646) 277-1254
Reed Anderson
(646) 277-1260
investor@petmeds.com
FAQ
Who is Peter Batushansky and what experience does he bring to PETS board?
How many independent directors has PETS appointed since 2024?
What recent leadership changes has PETS implemented in 2024-2025?
What is the current composition of PETS Board of Directors?
